{"doi":"10.1089/thy.2019.0514","title":"Acquired Secondary RAS Mutation in BRAF\n                    <sup>V600E</sup>\n                    -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors","abstract":"<jats:sec>\n                    <jats:title>Background:</jats:title>\n                    <jats:p>\n                      The BRAF\n                      <jats:sup>V600E</jats:sup>\n                      mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAF\n                      <jats:sup>V600E</jats:sup>\n                      -mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAF\n                      <jats:sup>V600E</jats:sup>\n                      -mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually develops. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer to develop future strategies to effectively treat these patients and improve survival.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:</jats:title>\n                    <jats:p>\n                      Herein, we describe four patients with thyroid cancer treated with selective BRAF inhibitors, who developed a RAS mutation in addition to the BRAF\n                      <jats:sup>V600E</jats:sup>\n                      mutation at progression.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:</jats:title>\n                    <jats:p>\n                      Patients 1 and 3 acquired a KRAS\n                      <jats:sup>G12V</jats:sup>\n                      mutation in the progressive tumor, patient 2 acquired a NRAS\n                      <jats:sup>Q61K</jats:sup>\n                      mutation in a progressive lymph node, and patient 4 acquired NRAS\n                      <jats:sup>G13D</jats:sup>\n                      mutation on liquid biopsy performed at the time of radiographic disease progression.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:</jats:title>\n                    <jats:p>Similar to the melanoma experience, the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.</jats:p>\n                  </jats:sec>","journal":"Thyroid®","year":2020,"id":652120,"datarank":0.687745121800586,"base_score":4.584967478670572,"endowment":4.584967478670572,"self_citation_contribution":0.687745121800586,"citation_network_contribution":0.0,"self_endowment_contribution":0.687745121800586,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":97,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":723301,"name":"Ramona Dadu","orcid":"0000-0002-3776-208X","position":1,"is_corresponding":false},{"id":1701000,"name":"Pryianka Iyer","orcid":null,"position":2,"is_corresponding":false},{"id":1701001,"name":"Kacey B. Wanland","orcid":null,"position":3,"is_corresponding":false},{"id":943958,"name":"Naifa L. Busaidy","orcid":"0000-0002-3808-6378","position":4,"is_corresponding":false},{"id":1701002,"name":"Anita Ying","orcid":null,"position":5,"is_corresponding":false},{"id":748062,"name":"Maria Gule-Monroe","orcid":"0000-0002-4418-3705","position":6,"is_corresponding":false},{"id":1701003,"name":"Jennifer R. Wang","orcid":null,"position":7,"is_corresponding":false},{"id":296139,"name":"Mark Zafereo","orcid":"0000-0001-7918-9739","position":8,"is_corresponding":false},{"id":1701004,"name":"Marie-Claude Hofmann","orcid":null,"position":9,"is_corresponding":false},{"id":239798,"name":"Maria E. Cabanillas","orcid":"0000-0002-5124-1811","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Acquired Secondary RAS Mutation in BRAF\n                    <sup>V600E</sup>\n                    -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors","abstract":"<jats:sec>\n                    <jats:title>Background:</jats:title>\n                    <jats:p>\n                      The BRAF\n                      <jats:sup>V600E</jats:sup>\n                      mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAF\n                      <jats:sup>V600E</jats:sup>\n                      -mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAF\n                      <jats:sup>V600E</jats:sup>\n                      -mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually develops. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer to develop future strategies to effectively treat these patients and improve survival.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:</jats:title>\n                    <jats:p>\n                      Herein, we describe four patients with thyroid cancer treated with selective BRAF inhibitors, who developed a RAS mutation in addition to the BRAF\n                      <jats:sup>V600E</jats:sup>\n                      mutation at progression.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:</jats:title>\n                    <jats:p>\n                      Patients 1 and 3 acquired a KRAS\n                      <jats:sup>G12V</jats:sup>\n                      mutation in the progressive tumor, patient 2 acquired a NRAS\n                      <jats:sup>Q61K</jats:sup>\n                      mutation in a progressive lymph node, and patient 4 acquired NRAS\n                      <jats:sup>G13D</jats:sup>\n                      mutation on liquid biopsy performed at the time of radiographic disease progression.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:</jats:title>\n                    <jats:p>Similar to the melanoma experience, the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":4.584967478670572,"endowment":4.584967478670572,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32216548","pmcid":"PMC7869871","openalex_id":"https://openalex.org/W3013546523","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P50 CA168505","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA016672","title":null}],"total_grants":2,"fwci":4.6231,"citation_percentile":0.96218734,"influential_citations":0,"citation_trend":[{"year":2020,"count":6},{"year":2021,"count":12},{"year":2022,"count":21},{"year":2023,"count":23},{"year":2024,"count":13},{"year":2025,"count":14},{"year":2026,"count":8}],"oa_status":"green","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7869871","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7869871","host_type":"repository"},{"url":"https://journals.sagepub.com/doi/full-xml/10.1089/thy.2019.0514","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/pdf/10.1089/thy.2019.0514","host_type":"publisher"},{"url":"https://doi.org/10.1089/thy.2019.0514","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32216548","host_type":"repository"}],"fields_of_study":["Melanoma and MAPK Pathways","Thyroid Cancer Diagnosis and Treatment","Cytokine Signaling Pathways and Interactions","Data Collection","Disease Progression","Genes, ras","Humans","Immunotherapy","Liquid Biopsy","Male","Middle Aged","Mutation","Mutation, Missense","Positron Emission Tomography Computed Tomography","Protein Kinase Inhibitors","Proto-Oncogene Proteins B-raf","Thyroid Cancer, Papillary","Thyroid Carcinoma, Anaplastic","Thyroid Neoplasms","Treatment Outcome"],"mesh_terms":["Positron Emission Tomography Computed Tomography","Liquid Biopsy","Thyroid Cancer, Papillary","Data Collection","Humans","Immunotherapy","Male","Middle Aged","Mutation","Genes, ras","Thyroid Neoplasms","Treatment Outcome","Disease Progression","Mutation, Missense","Protein Kinase Inhibitors","Proto-Oncogene Proteins B-raf","Thyroid Carcinoma, Anaplastic"],"keywords":["Dabrafenib","Trametinib","Medicine","Thyroid cancer","Anaplastic thyroid cancer","Cancer research","Vemurafenib","Papillary thyroid cancer","Mutation","V600E","Cancer","Melanoma","MEK inhibitor","Neuroblastoma RAS viral oncogene homolog","Oncology","Internal medicine","KRAS","Biology","Gene","Metastatic melanoma","MAPK/ERK pathway","Colorectal cancer","Genetics","Kinase","Drug resistance","Genetic Mutations","Kinase Inhibitors","Differentiated Thyroid Cancer","Molecular Testing","Mutational Pathways","Clonal Divergence"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"refseq"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T12:00:47.913948Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}